𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome

✍ Scribed by Cilia, R.; Siri, C.; Canesi, M.; Zecchinelli, A. L.; De Gaspari, D.; Natuzzi, F.; Tesei, S.; Meucci, N.; Mariani, C. B.; Sacilotto, G.; Zini, M.; Ruffmann, C.; Pezzoli, G.

Book ID
127357400
Publisher
BMJ Publishing Group
Year
2013
Tongue
English
Weight
143 KB
Volume
85
Category
Article
ISSN
0022-3050

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Switching from ergot to nonergot dopamin
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five-drug dose conversion table
✍ Katherine Grosset; Fiona Needleman; Graeme Macphee; Donald Grosset πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 67 KB

## Abstract Of 99 patients on ergot‐derived dopamine agonists informed about possible long‐term side effects, switching to a nonergot was undertaken in 88 (89%). There were adverse events in 26%. After 11 months, 82% were on their switch agonist and 93% were on any agonist. Switching dopamine agoni